SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SCLN
9.26
-0.21 (-2.22%)
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.25 - 9.51
52 week 4.68 - 9.87
Open 9.47
Vol / Avg. 290,231.00/412,997.00
Mkt cap 459.31M
P/E 16.18
Div/yield     -
EPS 0.57
Shares 49.60M
Beta 2.19
Inst. own 76%
Aug 10, 2015
Q2 2015 SciClone Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 12, 2015
SciClone Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Jun 11, 2015
SciClone Pharmaceuticals Inc Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
Jun 3, 2015
SciClone Pharmaceuticals Inc at Jefferies Global Healthcare Conference - 10:00AM EDT - Add to calendar
May 11, 2015
Q1 2015 SciClone Pharmaceuticals Inc Earnings Call - Webcast
May 11, 2015
Q1 2015 SciClone Pharmaceuticals Inc Earnings Release
Apr 15, 2015
SciClone Pharmaceuticals Inc at EBD Group ChinaBio Partnering Forum
Apr 14, 2015
SciClone Pharmaceuticals Inc at Needham Healthcare Conference
Mar 31, 2015
SciClone Pharmaceuticals Inc at Lychee Group LLC China Healthcare Investment Conference
Mar 11, 2015
Q4 2014 SciClone Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 26.70% 18.70%
Operating margin 28.25% 19.28%
EBITD margin - 19.95%
Return on average assets 19.74% 13.94%
Return on average equity 22.56% 16.70%
Employees 570 -
CDP Score - -

Address

950 Tower Ln Ste 900
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SciClone Pharmaceuticals, Inc. (SciClone) is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. Its business and corporate strategy is focused primarily on the People’s Republic of China (China). SciClone operates in two geographic segments, which include China and the rest of the world, including its operations in the United States and Hong Kong. The Company’s lead product is ZADAXIN (thymalfasin) is approved in 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant and certain cancers. SciClone’s marketed portfolio also includes Depakine, Tritace, Stilnox and Aggrastat. The Company sells ZADAXIN in various international markets through its wholly owned subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Officers and directors

Jon S. Saxe Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Friedhelm Blobel Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Wilson W. Cheung Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 46
Bio & Compensation  - Reuters
Hong Zhao Chief Executive Officer - China Operations
Age: 51
Bio & Compensation  - Reuters
Robert S. King Ph.D. Senior Vice President - Product Development and Supply Chain
Age: 48
Bio & Compensation  - Reuters
Raymond A. Low CPA Vice President - Finance, Controller
Age: 58
Bio & Compensation  - Reuters
Charles Meng Vice President - Compliance, General Counsel
Age: 52
Bio & Compensation  - Reuters
Lan Xie CPA Vice President - Finance, China Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Nancy T. Chang Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 66
Bio & Compensation  - Reuters